nAChR

Arecoline hydrobromide is a partial agonist of nicotinic (nAChR) and muscarinic acetylcholine receptors (mAChR). This naturally occurring psychoactive alkaloid possesses brain-penetrant properties and is known for its stimulation, alertness enhancement, anxiolytic effects, and anti-parasitic activity. Additionally, Arecoline hydrobromide can induce oxidative stress, making it valuable for research in neuropharmacology and related fields.

Acetylcholine chloride is a cholinergic agonist that acts primarily on nicotinic acetylcholine receptors (nAChRs). This compound exerts significant effects on the modulation of dopaminergic neuron activity, making it relevant for studying neurophysiological processes. Additionally, Acetylcholine chloride has been shown to inhibit the aggregation of p53 mutant peptides in vitro, highlighting its potential applications in cancer research and neurodegenerative disease studies.

Thermopsidine is a selective partial agonist of the α4β2 and α6β2 nicotinic acetylcholine receptors (nAChRs), exhibiting an EC50 value of 2.2 μM for the α4β2 subtype. This compound is valuable for studying cholinergic signaling pathways and exploring potential therapeutic avenues in neurodegenerative diseases and addiction research. Its specific targeting of nAChRs makes it a useful tool for evaluating receptor function and pharmacology.

Tribendimidine is an orally active broad-spectrum anthelmintic agent primarily targeting parasitic helminths. It demonstrates significant efficacy against Ascaris lumbricoides and Necator americanus, contributing to its potential use in treating intestinal helminth infections. Additionally, Tribendimidine acts as an agonist for L-type nicotinic acetylcholine receptors (nAChRs), further elucidating its mechanism of action in disrupting neurotransmission in helminths. This compound is valuable for research in parasitology and the development of novel anthelmintic therapies.

Droperidol is a butyrophenone compound primarily acting as a dopamine receptor antagonist. It inhibits the activation of GABA(A) and neuronal nicotinic acetylcholine receptors (nAChR), demonstrating IC50 values of 12.6 nM and 5.8 μM, respectively. This compound exhibits notable anesthetic and sedative properties, making it useful in research related to neuropharmacology and anesthesiology.

Mivacurium dichloride is a short-acting non-depolarizing neuromuscular blocking agent that acts as a skeletal muscle relaxant. It exerts its pharmacological effects by binding to the nicotinic acetylcholine receptor (nAChR), thereby inhibiting the depolarizing action of acetylcholine at the neuromuscular junction. This compound is utilized in clinical settings for facilitating intubation and providing muscle relaxation during surgical procedures.

(+)-Sparteine is a natural alkaloid that functions as a competitive inhibitor of nicotinic acetylcholine receptors (nAChRs). By blocking these receptors in neurons, it serves as a ganglionic blocking agent, impacting neurotransmission. This compound is utilized in research applications related to neurotransmitter signaling and the study of ganglionic transmission.

MB327 is a bipyridine nonoxime compound that functions as a resensitizer of nicotinic acetylcholine receptors (nAChRs). It effectively restores neuromuscular function by reversing carbachol-induced desensitization in a typical type II positive allosteric modulatory manner. Additionally, MB327 has potential applications in neutralizing nerve agent poisoning, making it valuable for research in neuropharmacology and toxicology.

Adiphenine is a non-competitive inhibitor of nicotinic acetylcholine receptors (nAChR), exhibiting IC50 values of 1.9 μM for α1, 1.8 μM for α3β4, 3.7 μM for α4β2, and 6.3 μM for α4β4. This compound demonstrates significant anticonvulsant properties, making it valuable for studies related to seizure disorders and neuropharmacology. Its selective action on various nAChR subtypes positions Adiphenine as a useful tool for exploring the role of these receptors in different biological contexts.